Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02454595 · ClinicalTrials.gov registry record
Registry to Measure the Impact of Adding Genomic Testing
A clinical trial, sponsored by Myriad Genetic Laboratories.
- Terminated
- Registry status
- 116
- Enrollment target
NCT02454595: Clinical Trial study, sponsored by Myriad Genetic Laboratories.
NCT02454595 is a clinical trial that was terminated before completion, run by Myriad Genetic Laboratories. The registered enrollment target is 116 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02454595 was terminated before completion, sponsored by Myriad Genetic Laboratories.
- TERMINATED
- Registry status
- 116 participants
- Enrollment target
Study Summary
This is a prospective open registry to measure the impact on first-line therapy of genomic testing of biopsy tissue from recently diagnosed treatment-naïve patients with early stage localized prostate cancer. Physicians will complete a series of questionnaires. Biopsy tissue will be tested using the Prolaris® genomic test and a relative cancer aggressiveness score will be shared with the physician and the patient.
Interventions
- BEHAVIORAL Registry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2014-11 |
| Est. Completion | 2017-07-03 |
Why NCT02454595 stopped before completion
NCT02454595 is an observational study that tracks outcomes without assigning an intervention. The registered 116 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Registry is the first listed.
NCT02454595 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02454595 about?
NCT02454595 is a clinical study titled "Registry to Measure the Impact of Adding Genomic Testing". This is a prospective open registry to measure the impact on first-line therapy of genomic testing of biopsy tissue from recently diagnosed treatment-naïve patients with early stage localized prostate cancer. Physicians will complete a series of questionnaires. Biopsy tissue will be tested using the...
What is the current status of trial NCT02454595?
This trial is currently terminated. The enrollment target is 116 participants. The study started on 2014-11. Estimated completion is 2017-07-03.
What interventions are being tested in trial NCT02454595?
The interventions under investigation include: Registry (BEHAVIORAL).
Who is sponsoring clinical trial NCT02454595?
This trial is sponsored by Myriad Genetic Laboratories, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03014687 · 116 participants · Phase 4
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
- NCT03214562 · 116 participants · Phase 1
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- NCT03847467 · 116 participants · Phase 1
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
- NCT04222413 · 116 participants · Phase 1
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia